Patents by Inventor Dennis J. Hartigan-O'Connor
Dennis J. Hartigan-O'Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230087396Abstract: Methods and compositions are disclosed for inducing immune responses against one or more antigens in a mammal.Type: ApplicationFiled: November 15, 2022Publication date: March 23, 2023Applicant: The Regents of The University of CaliforniaInventor: Dennis J. Hartigan-O'Connor
-
Publication number: 20220411484Abstract: Provided herein are methods for preventing or treating a human immunodeficiency virus (HIV) infection or a simian immunodeficiency virus (SIV) infection in a subject. The methods include administering to the subject (a) a reservoir-depleting agent that binds to a host protein on a reservoir cell, and (b) an antiviral vaccine.Type: ApplicationFiled: July 12, 2022Publication date: December 29, 2022Applicant: The Regents of The University of CaliforniaInventor: Dennis J. Hartigan-O'Connor
-
Publication number: 20190127758Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: ApplicationFiled: November 7, 2018Publication date: May 2, 2019Inventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Patent number: 10167485Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: August 12, 2016Date of Patent: January 1, 2019Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20170204431Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: ApplicationFiled: August 12, 2016Publication date: July 20, 2017Inventors: Jeffrey S. CHAMBERLAIN, Dennis J. Hartigan-O'Connor
-
Patent number: 9453240Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: January 24, 2014Date of Patent: September 27, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20140193858Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: ApplicationFiled: January 24, 2014Publication date: July 10, 2014Applicant: The Regents of the University of MichiganInventors: Jeffrey S. CHAMBERLAIN, Dennis J. HARTIGAN-O'CONNOR
-
Patent number: 8637313Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 16, 2010Date of Patent: January 28, 2014Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20110033926Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: ApplicationFiled: September 16, 2010Publication date: February 10, 2011Inventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Patent number: 7820441Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 21, 2001Date of Patent: October 26, 2010Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20040087029Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: ApplicationFiled: October 9, 2003Publication date: May 6, 2004Inventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Patent number: 6127598Abstract: The present invention features mouse models for Nkx-2.2 gene function and for Nkx-6.1 gene function, wherein the transgenic mouse is characterized by having a defect in Nkx-2.2 gene function or a defect in Nkx-6.1 gene function (where, because Nkx-2.2 acts upstream of Nkx-6.1, a defect in Nkx-2.2 gene function affects Nkx-6.1 gene function) and by having a decreased number of insulin-producing cells relative to a normal mouse. Where the transgenic mouse contains a defect in Nkx-2.2 gene function, the mouse is further characterized by a decreased number of serotonin-producing cells relative to a normal mouse. The transgenic mice may be either homozygous or heterozygous for the Nkx-2.2 or Nkx-6.1 defect.Type: GrantFiled: July 25, 1997Date of Patent: October 3, 2000Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, John L.R. Rubenstein, Lori Sussel, Maike Sander, Dennis J. Hartigan-O'Connor, Roger A. Pedersen, Juanito J. Meneses
-
Patent number: 6057158Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.Type: GrantFiled: May 18, 1999Date of Patent: May 2, 2000Assignee: Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor